• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Authors » Daniel Carlat, MD

Articles by Daniel Carlat, MD

Computer Assisted Psychiatry: An Introduction and Road Test

April 1, 2015
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
There are plenty of ways that we use technology in psychiatric practice these days—including e-prescribing, electronic health records, referring patients to websites for psychoeducation, etc. But when was the last time you referred a patient to their computer for psychotherapy? Well, it may be time to consider it.
Read More

Namzaric and Other Cognitive Enhancers for Dementia

March 1, 2015
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
There’s a new medication on the market for the treatment of dementia—the first to come along in several years.
Read More

Benzodiazepine Use and Alzheimer’s Risk

March 1, 2015
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
If you’re like most psychiatrists, you get your fair share of older folks who come into the office complaining of difficulties with sleep or with significant symptoms of anxiety.
Read More

Latuda: An Evaluation of Its Usefulness

February 1, 2015
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
With nine other atypical antipsychotics already on the market (some of which are available as generics), did we really need another one? Given the pesky side effects of antipsychotics, maybe we did. Let’s take a look at what we know so far about Latuda (lurasidone) in an effort to figure out how to incorporate it into our clinical toolbox. Latuda was first approved by the US Food and Drug Administration (FDA) for use in schizophrenia in late 2010.
Read More

The New Emphasis on Community Functioning in Schizophrenia

February 1, 2015
Dost Ongur, PhD, MD and Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Dost Ongur, PhD, MD Chief, Psychotic Disorders Division, McLean Hospital, Belmont, MA Associate Professor of Psychiatry, Harvard Medical School Dr. Ongur has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.   Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Learn about the new emphasis on community functioning for patients with schizophrenia, in an interview with Dost Ongur, MD, PhD, chief of the psychotic disorders division at McLean Hospital and an associate professor of psychiatry at Harvard Medical School.
Read More

Maintenance of Certification: What You Need to Know

September 1, 2014
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Since I last wrote about MOC in 2010, the most relevant news has not been within the program itself, but in the increasingly rancorous reaction against its requirements from physicians of all specialties. Regardless, it doesn’t look like ABPN is going to be ditching MOC any time soon, so this article pretty much lays out what you have to do, without (much) editorializing.
Read More

A Boatload of New Data on Stimulants and Cardiac Events

February 1, 2012
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
In 2006, an FDA panel recommended all manufacturers of stimulants to add a “black box” warning about an increased risk of “serious cardiovascular events.”
Read More

Nuedexta for Pseudobulbar Affect

January 1, 2012
Steve Balt, MD and Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb. Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Nuedexta is a combination of dextromethorphan (DM) and quinidine sulfate. You might reasonably ask why these two agents would have ever been considered as a treatment for PBA.
Read More

Drug Interactions in Psychiatry: A Practical Review

February 1, 2011
Jessica L. Gören, PharmD, BCPP and Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jessica L. Gören, PharmD, BCPP Associate professor, University of Rhode Island Instructor in Psychiatry, Harvard University Clinical psychiatric pharmacist, Cambridge Health Alliance Daniel Carlat, MD Associate clinical professor, Tufts University School of Medicine Dr. Goren and Dr. Carlat have disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
In this article we’ll survey those drug interactions that are most likely to become troublesome in day to day psychiatric practice.
Read More

Long Acting Injectable Antipsychotics: A Primer

December 1, 2010
Kelly Gable, PharmD, BCPP and Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Kelly Gable, PharmD, BCPP Assistant professor of pharmacy practice Southern Illinois University, Edwardsville, School of Pharmacy Daniel Carlat, MD Editor-in-chief, The Carlat Psychiatry Report
They used to be called “depot” antipsychotics, but the powers that be have renamed them “long acting injectables” (LAIs), presumably to help remove some of the stigma associated with their use. But no matter what you call them, suddenly every drug company is racing to introduce its own LAI neuroleptic.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 … 17 18 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2637648401.jpg
    General Psychiatry

    Psychopharm Secrets: Coming Off Meds

    There’s a hidden placebo response to watch for when patients stop meds on their own.
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.